News | Radiopharmaceuticals and Tracers | January 23, 2024

Successful completion of contractual site acceptance tests, with 70 MeV cyclotron now fully operational

Successful completion of contractual site acceptance tests, with 70 MeV cyclotron now fully operational

January 23, 2024 — IBA, a world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical production solutions, is pleased to announce that the Cyclone 70 system installed at the iThemba Laboratory for Accelerator Based Sciences (iThemba LABS) in Cape Town, one of the research facilities of the National Research Foundation of South Africa, has been fully commissioned enabling iThemba LABS to start transferring the production of radioisotopes from their existing accelerator to the new Cyclone 70 system. 

Acceptance testing was completed in December 2023, with the cyclotron reaching full beam power (750µA) at full energy. This 70 MeV cyclotron will be dedicated to the production of next-generation medical isotopes used mainly in the diagnosis of critical illnesses. The machine will be used primarily for the manufacture of Strontium-82 for use in the diagnosis of cardiovascular disease, as well as for production of Germanium-68 for use in positron emission tomography (PET) imaging. 

Dr Le Roux Strydom, Head of Accelerator Operations & Technical Support at iThemba LABS, said: “We are extremely pleased with the outcome of this project. The project management was exceptional and having direct access to IBA’s experts added significant value to our experience. Our confidence in IBA’s high energy systems has been solidified by their demonstrated expertise, particularly with the 70 MeV cyclotron. We eagerly anticipate our continued collaboration with IBA, a proven leader in cyclotron technology.” 

Bruno Scutnaire, President at IBA RadioPharma Solutions, added: “We are proud to announce yet another demonstration of our expertise in 70 MeV machines with this project, with installation successfully completed and iThemba LABS ready to start the production of Strontium-82 and other radioisotopes. This latest accomplishment strengthens our leading position in cyclotron technology and attests to our commitment to delivering cutting-edge solutions to meet our clients’ needs. To date, six Cyclone® 70 MeV machines and over 35 cyclotrons of 30 MeV have been installed worldwide. We see a growing interest for these high energy machines, driven by an increasing number of clinical trials exploring new diagnostic or radiotherapeutic molecules.” 

For more information: www.iba-worldwide.com 


Related Content

News | ASTRO

Oct. 5, 2026 — The American Society for Radiation Oncology (ASTRO) recognized the recipients of its 2026 Gold Medal ...

Time October 07, 2026
arrow
News | ASTRO

Sept. 29, 2026 — The American Society for Radiation Oncology (ASTRO) has named Siemens Healthineers the inaugural ...

Time September 29, 2026
arrow
News | Proton Therapy

Sept. 28, 2026 — Penn Medicine and Ion Beam Applications (IBA) have formed Noventra Oncology Alliance, a new joint ...

Time September 28, 2026
arrow
News | ASTRO

Sept. 22, 2026 — Leading experts in radiation therapy from the Abramson Cancer Center (ACC) of the University of ...

Time September 24, 2026
arrow
News | PET Imaging

Sept. 22, 2026 — Researchers from the Keck School of Medicine of USC are developing a new “plug-and-play” platform that ...

Time September 23, 2026
arrow
News | ASTRO

Sept.16, 2026 — For appropriately selected patients with muscle-invasive bladder cancer, preserving the bladder can be a ...

Time September 17, 2026
arrow
News | Radiology Imaging

Sept. 1, 2026 — Leo Cancer Care and GE HealthCare have announced that the two companies intend to work together on GE ...

Time September 11, 2026
arrow
News | ASTRO

Sept. 9, 2026 — The 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting, will take place Sept. 26 to 30 ...

Time September 11, 2026
arrow
News | Women's Health

Sept. 1, 2026 — On Sept. 24, 2026 at 1 p.m. EDT, Siemens Healthineers will present a webinar on "Advancing Women's ...

Time September 03, 2026
arrow
News | PET Imaging

Aug. 14, 2026 — Lantheus Holdings recently announced U.S. Food and Drug Administration (FDA) approval of Tauklarify ...

Time August 20, 2026
arrow
Subscribe Now